Effects of SGLT2 inhibitors on triglyceride-derived indices among coronary heart disease patients with varying diabetes control status: a prospective cohort study

Back

ESC2025 Premium Access

Effects of SGLT2 inhibitors on triglyceride-derived indices among coronary heart disease patients with varying diabetes control status: a prospective cohort study

Session: What's new for GLP-1 agonist and SGLT2 inhibitor cardiovascular pharmacotherapy?

Topic: Antidiabetic Pharmacotherapy

Speaker: Professor N. Wu (Beijing, CN)

Event: ESC Congress 2025

Congress Presentation

Add to my library

About the speaker

Professor Na-Qiong Wu

Fuwai Hospital, CAMS and PUMC, Beijing (China)

0 follower

5 more presentations in this session

Semaglutide effects on incidence and reoccurrence of atrial fibrillation in the SELECT trial

Speaker: Doctor J. Plutzky (Boston, US)

Effects of oral semaglutide on heart failure outcomes in people with type 2 diabetes and atherosclerotic cardiovascular disease and/or chronic kidney disease participating in SOUL trial

Speaker: Professor R. Pop-Busui (Portland, US)

Vagal activity related events and GLP-1 receptor agonists

Speaker: Mr A. Holt (Copenhagen, DK)

Sodium-Glucose Co-Transporter 2 inhibitors and cardiovascular outcomes: a trial-similar population vs. a broad population

Speaker: Doctor P. Yazdanfard (Hilleroed, DK)

Cardiovascular outcomes in sustained use of glucagon like peptide inhibitors: a trial inspired population vs. a broad population

Speaker: Ms K. Soerensen (Copenhagen, DK)

Access the full session

What's new for GLP-1 agonist and SGLT2 inhibitor cardiovascular pharmacotherapy?

Speakers: Professor N. Wu, Doctor J. Plutzky, Professor R. Pop-Busui, Mr A. Holt, Doctor P. Yazdanfard...

Access

Video

About the event

ESC Congress 2025

29 August - 1 September 2025

Sessions Presentations

Congress

ESC 365 is supported by

Explore sponsored resources

Explore sponsored resources